Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib

Pavan Bachireddy; Catherine J Wu

doi:10.1158/1078-0432.CCR-15-3106

Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib

Clin Cancer Res. 2016 Apr 1;22(7):1547-9. doi: 10.1158/1078-0432.CCR-15-3106. Epub 2016 Feb 4.

Authors

Pavan Bachireddy¹, Catherine J Wu²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of MIT and Harvard, Cambridge, Massachusetts. Harvard Medical School, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of MIT and Harvard, Cambridge, Massachusetts. Harvard Medical School, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. [email protected].

Abstract

The clinical success of agents targeting the B-cell receptor signaling pathway in chronic lymphocytic leukemia (CLL) may also derive from disrupting the CLL microenvironment. Investigation of the immunomodulatory effects of these agents illuminates the unique immunobiology of CLL and highlights potential targets for dismantling the chronic inflammatory drive. See related article by Niemann et al., p. 1572.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

B-Lymphocytes / metabolism
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Protein Kinase Inhibitors / pharmacology*
Signal Transduction / drug effects

Substances

Protein Kinase Inhibitors

Abstract

Publication types

MeSH terms

Substances

Grants and funding